Vicuron Pharmaceuticals to Present at the Pacific Growth Equities Conference
June 07 2004 - 1:48PM
PR Newswire (US)
Vicuron Pharmaceuticals to Present at the Pacific Growth Equities
Conference KING OF PRUSSIA, Pa., June 7 /PRNewswire-FirstCall/ --
Vicuron Pharmaceuticals Inc. (NASDAQ:MICU) today announced that Dov
A. Goldstein, M.D., Executive Vice President and CFO, will present
at the Pacific Growth Equities Life Sciences Conference at 10:00
a.m. Pacific Time (1:00 p.m. Eastern Time) on Wednesday, June 9,
2004 at The Mark Hopkins Inter-Continental Hotel in San Francisco,
Calif. To access the live audio broadcast or the subsequent
archived recording log on to http://www.vicuron.com/ and click on
the investor relations section. Please connect to the website
several minutes prior to the start of the webcast to ensure
adequate time for any software download that may be necessary. The
live broadcast will be archived for 30 days. About Vicuron Vicuron
Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital
medicine for seriously ill patients in North America and Europe.
The company received an approvable letter for its lead product
anidulafungin in May 2004. The company's other lead product,
dalbavancin, a novel intravenous antibiotic for the treatment of
serious Gram-positive infections, is in Phase III clinical trials.
The company's versatile research engine integrates industry-leading
expertise in functional genomics, natural products discovery,
mechanism-based drug design and combinatorial and medicinal
chemistry. These approaches are yielding promising novel and
next-generation compounds, many of which are in the later stages of
preclinical development. In addition, the company has research and
development collaborations with leading pharmaceutical companies,
such as Pfizer and Novartis. Forward-Looking Statements This news
release and the presentation contain forward-looking statements
that predict or describe future events or trends. The matters
described in these forward-looking statements are subject to known
and unknown risks, uncertainties and other unpredictable factors,
many of which are beyond Vicuron's control. Vicuron faces many
risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements,
including the possibilities that clinical trials and the results
thereof might be delayed, that the timing of the filing of any new
drug application might be delayed, that subsequent clinical trials
might indicate that a product candidate is unsafe or ineffective,
that any filed new drug application may not be approved, that
ongoing proprietary and collaborative research might not occur or
yield useful results, that a third party may not be willing to
license our product candidates on terms acceptable to us or at all,
that competitors might develop superior substitutes for their
products or market them more effectively, that a sales force may
not be developed as contemplated and that one or more of its
product candidates may not be commercialized successfully. The
reports that Vicuron files with the U.S. Securities and Exchange
Commission contain a fuller description of these and many other
risks to which Vicuron is subject. Because of those risks,
Vicuron's actual results, performance or achievements may differ
materially from the results, performance or achievements
contemplated by its forward- looking statement. The information set
forth in this news release and the presentation represent
management's current expectations and intentions. Vicuron assumes
no responsibility to issue updates to the forward-looking matters
discussed in this news release. DATASOURCE: Vicuron Pharmaceuticals
Inc. CONTACT: Jeffrey S. Tarmy, +1-617-939-3316, or , for Vicuron
Pharmaceuticals Inc. Web site: http://www.vicuron.com/
Copyright
Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Vicuron Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Vicuron Pharmaceuticals (MM) News Articles